
    <rss version="2.0" xmlns:itunes="http://www.itunes.com/dtds/podcast-1.0.dtd">
      <channel>
        <title>Articles tagged with In-licensing from Medical Marketing and Media</title>
        <link>http://www.mmm-online.com/inlicensing/topic/19592/</link>
        <description>Articles tagged with In-licensing from Medical Marketing and Media</description>
        <itunes:author>MMM</itunes:author>
        <itunes:subtitle></itunes:subtitle>
        <itunes:summary></itunes:summary>
        <itunes:owner>
            <itunes:name></itunes:name>
            <itunes:email>mmmsubs@haymarketmedia.com</itunes:email>
        </itunes:owner>
        <itunes:category text="BUSINESS">
            <itunes:category text="BUSINESS NEWS" /> 
        </itunes:category> 
        <itunes:image href='http://media.haymarketmedia.com/images/32/MMM_logo_28402_31022.gif'></itunes:image>
        <itunes:explicit>no</itunes:explicit>
  
        <item>
          <title>Pharmas to biotechs: let&apos;s make a deal</title>
          <description>Having finally accepted that external R&amp;D is the future, big pharmas are snapping up earlier-stage biotechs and biologics, but they&apos;re not betting the farm on them, thanks to pre-nup-like earnout deals.</description>
          <link>http://www.mmm-online.com/pharmas-to-biotechs-lets-make-a-deal/article/290613/</link>
          <pubDate>Thu, 25 Apr 2013 20:51:35 GMT</pubDate>
          <itunes:summary>Having finally accepted that external R&amp;D is the future, big pharmas are snapping up earlier-stage biotechs and biologics, but they&apos;re not betting the farm on them, thanks to pre-nup-like earnout deals.</itunes:summary>
          <itunes:author>MMM</itunes:author>
          
        </item>
  
        <item>
          <title>Company news: Licensepalooza -- Janssen/Evotec, AstraZeneca/Link Medicine, Eisai/Verastem</title>
          <description>J&amp;J&apos;s Janssen unit inked a deal with Evotec AG and Harvard University to license a portfolio of diabetes drugs and biologics designed to trigger the regeneration of insulin-producing beta cells.</description>
          <link>http://www.mmm-online.com/company-news-licensepalooza--janssenevotec-astrazenecalink-medicine-eisaiverastem/article/250005/</link>
          <pubDate>Thu, 12 Jul 2012 17:00:25 GMT</pubDate>
          <itunes:summary>J&amp;J&apos;s Janssen unit inked a deal with Evotec AG and Harvard University to license a portfolio of diabetes drugs and biologics designed to trigger the regeneration of insulin-producing beta cells.</itunes:summary>
          <itunes:author>MMM</itunes:author>
          
        </item>
  
      </channel>
    </rss>  
  